InflaRx to Present at Upcoming Investor Conferences
Jena, Germany, January 4, 2018 – InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, will present at the following conferences:
J.P. Morgan Annual Healthcare Conference
Date: January 8-11, 2018,
Presentation: Wed, 10th Jan 8:00 am PST (5:00 pm CET)
Venue: San Francisco, CA, USA
Presenter: Prof. Niels Riedemann, Chief Executive Officer of InflaRx
Arnd Christ, Chief Financial Officer of InflaRx
LEERINK Partners 7th Annual Global Healthcare Conference
Date: February 14-15, 2018
Presentation: Wed, 14th Feb 1:30 pm EST (7:30 pm CET)
Venue: New York, NY, USA
Presenter: Prof. Niels Riedemann, Chief Executive Officer of InflaRx
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the NASDAQ Global Select Market in the United States under the trading symbol “IFRX.”
Contacts:
InflaRx N.V.
Prof. Dr. Niels C. Riedemann - CEO
Email: info[at]inflarx.de
Tel: +49-3641-508180
